Crystal structure of OspA ST1 from B. burgdorferi bound to monoclonal antibody LA-2
Preclinical assessment of an investigational mRNA lipid nanoparticle OspA vaccine for Lyme disease
DIQMTQSPSSLSATLGGKVTITCKASQDINKYIAWYQHKPGKGPRLLIHYTSTLQPGNPSRFSGSGSGRDYSFSISNLEA EDIAIYYCLQYDNLQRTFGGGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVL NSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNE
QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMYWVKQAPGKGLKRMGWINTETGEPTYADDFKGRFALSLDTSASTAY LHISNLKNEDTATYFCARGLDSWGQGTSVTVSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLS SSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPS
MKAILVVLLYTFTTANAEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELKGTSDKNNGAGVLEGVKADKSKVKL TISDDLGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGFILE GRFTAEKTTLVVKEGTVTLSKDISKSGEVSVELQDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQY DSNGVKLEGSAVEITKLDEIKNALKLVPRGSGHHHHHHHHSAWSHPQFEK
15 mg/mL, 0.1 M Magnesium Acetate tetrahydrate and 10% (w/v) PEG 3350; cryo 25%(v/v) Glycerol
Hydrogens have been added in their riding positions
Lyme disease, Outer Surface Protein A (OspA), IMMUNE SYSTEM
Local NCS retraints between domains: 1 2
Local NCS retraints between domains: 3 4
Local NCS retraints between domains: 5 6
EKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELKGTSDKNNGSGVLEGVKADKSKVKLTISDDLGQTTLEVFKED GKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYVLEGTLTAEKTTLVVKEGTV TLSKNISKSGEVSVELNDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQYDSNGTKLEGSAVEITKL DEIKNALK